Lexeo Therapeutics Appoints Kyle Rasbach as CFO-March 2024-www.financetom.com

Lexeo Therapeutics Appoints Kyle Rasbach as CFO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Lexeo Therapeutics Appoints Kyle Rasbach as CFO

Dec 19, 2024 8:07 AM

10:41 AM EST, 12/19/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Thursday it appointed Kyle Rasbach as chief financial officer.

Rasbach was most recently working as chief business officer at Zentalis Pharmaceuticals ( ZNTL ) , according to the company.

Shares of Lexeo were down 4.4% in recent trading.

Price: 6.08, Change: -0.28, Percent Change: -4.40

Previous page： BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics Next page： Hapbee to Raise $1.5 Million in Private Placement

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics

Jun 26, 2025

June 26 (Reuters) - NRX Pharmaceuticals Inc ( NRXP ): * HOPE THERAPEUTICS, INC. AND NRX PHARMACEUTICALS, INC. ( NRXP ) ANNOUNCE AGREEMENT TO ACQUIRE INTEREST IN COHEN AND ASSOCIATES, LLC FOR HOPE'S NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS * NRX PHARMACEUTICALS INC ( NRXP ) - HOPE TO PURCHASE 49% INTEREST IN COHEN AND ASSOCIATES * NRX PHARMACEUTICALS INC (...

Hapbee to Raise $1.5 Million in Private Placement

Jun 26, 2025

08:19 AM EDT, 06/26/2025 (MT Newswires) -- Hapbee Technologies ( HAPBF ) , which gained 18% on Wednesday, overnight, announced a non-brokered private placement consisting of up to 15.1 million units at $0.10 apiece for $1.5 million. The company also appointed Ahsan Ashraf as its new chief technology officer. Each Unit will consist of one subordinate voting common share and...

Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients

Jun 26, 2025

08:16 AM EDT, 06/26/2025 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Thursday it was able to identify a patient selection biomarker in its exploratory phase 2 proof-of-concept trial of ALTO-203 in major depressive disorder patients with elevated levels of anhedonia. ALTO-203 demonstrated clear effects on objective measures of attention and wakefulness, in the phase 2 trial, the company...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...